200 million antimicrobial injections! Shi Shi medicine won the first review

Pharmaceutical Network January 18, a few days ago, Shisi Pharmaceutical Group issued a notice that its wholly-owned subsidiary Shijiazhuang four drugs lactic acid cyclopropanoxacin sodium chloride injection was approved through a consistent evaluation, becoming the first enterprise to evaluate the product.
meters intranet data show that in recent years in China's public medical institutions terminal propylene saccharin injection sales growth rate of more than 15%, in 2019 exceeded 200 million yuan, of which, Guangzhou Nanxin pharmaceutical market share accounted for the largest, more than 60%.
sodium chloride injections for lactic acid cycloacine are fluoroquinoquinosterone antibiotics used to treat or prevent various types of bacterial infections.
source: Mi-Net one-click search Mi-Net data show that in recent years in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal acrylic injection sales growth rate of more than 15%, in 2019 exceeded 200 million yuan, of which, Guangzhou Nanxin pharmaceutical market share accounted for the largest, more than 60%.
lactic acid cycloproxacin sodium chloride injection manufacturers have Guangzhou Nanxin Pharmaceuticals, Bayer, Sichuan Colum Pharmaceuticals, Shandong Qidu Pharmaceuticals and more than 80.
present, the product only Shijiazhuang four drugs to supplement the application has been approved, in addition, Guangzhou Nanxin pharmaceutical consistency evaluation supplementary application in the review and approval (in the drug review center).
source: announcement of listed companies, Mienet database